Latest Update - March 2015 - New immunohistochemical tests available
The variable behaviour of mast cell tumours and melanomas in dogs makes it difficult for many veterinary practitioners to offer their clients an accurate prognosis and the best treatment.
We are excited to announce that we have implemented immunohistochemical tests, many pioneered at the Trust, for assessing tumour proliferation, which is one of the most important predictors of the risk of metastases and recurrence.
The Ki-67 proliferative marker, usually investigated in canine mast cell tumours of the skin, can now also be assessed at the AHT in mast cell tumours arising in the subcutis and in melanomas arising in the oral cavity, lips, skin, and digits.
In addition, we also offer the evaluation of a newly discovered proliferative marker (Minichromosome Maintenance Protein -7) for canine cutaneous mast cell tumours which has been revealed to be significantly associated with patients’ survival.
For more information, please contact Christine Gird on firstname.lastname@example.org
View relevant research papers on Prognostic Evaluation of Ki67 Threshold Value in Canine Melanoma, Evaluation of Minichromosome Maintenance Protein 7 as a Prognostic Marker in Canine Cutaneous Mast Cell Tumours, and the Association of Ki67 Index with Prognosis for Intermediate-grade Canine Cutaneous Mast Cell Tumours.
Immunohistochemistry (IHC) is playing an increasingly important role in modern veterinary pathology. It is a valuable tool in both diagnosis and research of infectious and neoplastic diseases in animals. A key benefit, IHC is performed on the same tissue samples on which histological evaluation is made; therefore IHC does not require additional sample collection or invasive procedures. This also allows for direct visual comparison of the targeted lesion with the tested antibody.
Immunohistochemistry is used to identify specific proteins within cells, tissues or organisms via antibodies which bind to the protein in question. This binding is followed by a chemical reaction which results in production of a colour which can be seen under the microscope.
Immunohistochemistry at the Animal Health Trust (AHT) is performed on a state-of-the-art automated system designed specifically for this procedure, allowing processing of large volumes of cases and ensuring reproducibility, accuracy and a fast turn-around time. ‘Manual,’ or bench-side, IHC is also performed for novel research antibodies. All IHC protocols at the AHT are standardised and optimised and quality control is strictly monitored with every test performed, including known positive controls.
Here at the AHT, focus is primarily on diagnostic and/or prognostic markers for neoplastic diseases, principally in dogs, cats, and horses. This may include classification of ‘undifferentiated’ tumours and/or lymphomas, evaluation of metastatic tumours for site of origin, and identification of micro-metastatic disease in sentinel lymph node biopsies taken from cancer patients. This technique plays an important role in assessing prognosis in some cancer patients (e.g. via proliferative proteins, such as Ki67 in mast cell tumours) and directing treatment protocols. Identification of infectious agents (e.g. Equine Herpesvirus) aids in treatment and preventing epidemics.
For enquiries about our immunohistochemistry services, please contact Christine Gird by emailing email@example.com or telephoning 01638 552993.
|The Animal Health Trust (AHT) is extremely grateful to the Horserace Betting Levy Board (HBLB), Racehorse Owners Association (ROA) and Thoroughbred Breeders’ Association (TBA) for their continued combined contribution to the AHT’s Equine Infectious Disease Service, which in particular supports key staff within the Diagnostic Laboratory and Pathology Service and allows enhanced investigation and control of significant equine infectious diseases in the United Kingdom.